Stockscreener 앱 받기
529.24
1.42%
7.40
전일 마감가:
$521.84
열려 있는:
$518.25
하루 거래량:
951.32K
Relative Volume:
0.74
시가총액:
$53.25B
수익:
$14.09B
순이익/손실:
$4.50B
주가수익비율:
13.47
EPS:
39.28
순현금흐름:
$2.96B
1주 성능:
+7.30%
1개월 성능:
-7.82%
6개월 성능:
-27.63%
1년 성능:
-48.44%
1일 변동 폭
$514.98
$529.55
1주일 범위
$494.42
$529.99
52주 변동 폭
$476.49
$1,211.20
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Handelsbanken Fonder AB - MarketBeat
New England Research & Management Inc. Invests $384,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | - GuruFocus
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fifth Third Bancorp - MarketBeat
1,547 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Harbor Capital Advisors Inc. - MarketBeat
Regeneron’s SWOT analysis: stock faces eylea challenges, pipeline potential - Investing.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Miracle Mile Advisors LLC - MarketBeat
Tounjian Advisory Partners LLC Invests $662,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Research Analysts Offer Predictions for REGN FY2026 Earnings - MarketBeat
23andMe co-founder Anne Wojcicki has bought back the company - NewsBytes
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wedmont Private Capital - MarketBeat
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm - MSN
Atwood & Palmer Inc. Has $26.62 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Anne Wojcicki to buy back 23andMe and its data for $305 million - MSN
Regeneron requests bundling ban after trial win - Global Competition Review
Former 23andMe CEO wins bidding war against Regeneron - FirstWord
23andMe's founder Anne Wojcicki wins bid for DNA testing firm - MSN
23andMe founder buys back genetic testing company in second auction - Financial Times
23andMe’s founder Anne Wojcicki wins bid for bankrupt DNA testing firm - New York Post
23andMe’s founder Anne Wojcicki wins bid for DNA testing firm - The Mighty 790 KFGO
Anne Wojcicki wins back 23andMe in bankruptcy court sale - The Business Journals
Regeneron (REGN) Chosen as Backup Bidder in 23andMe Asset Sale | REGN Stock News - GuruFocus
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process - Benzinga
Avanza Fonder AB Has $5.57 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN
Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
NorthCrest Asset Manangement LLC Has $7.55 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2,141 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by RMR Wealth Builders - MarketBeat
Pallas Capital Advisors LLC Takes $426,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Breakthroughs in Autoimmune Treatment Propel Interleukin - openPR.com
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch - Yahoo Finance
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor? - MSN
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples - BioSpace
Greenwood Capital Associates LLC Invests $5.35 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks - insights.citeline.com
When (REGN) Moves Investors should Listen - news.stocktradersdaily.com
Merit Financial Group LLC Buys 761 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $836.48 - MarketBeat
Regeneron Licenses Weight Loss Drug and Shares Muscle Preservation Study Data as Bluebird Bio Goes Private - geneonline.com
TB Alternative Assets Ltd. Acquires New Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MSN
Assenagon Asset Management S.A. Has $305.31 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
What’s Regeneron’s $256 Million Plan for 23andMe? - River Journal Online
Lake Hills Wealth Management LLC Purchases Shares of 616 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe Privacy Reviewer’s Law Firm Discloses Work for Regeneron - Bloomberg Law News
23andMe lawsuit: 27 states, including Illinois, Wisconsin, sue to block sale of personal genetic data to Regeneron Pharmaceuticals - ABC7 Chicago
Shareholders Filed a Lawsuit Against Regeneron Pharmaceuticals for Misleading Pricing Practices - TradingView
States sue to block the sale of 23andMe personal genetic data - NBC10 Philadelphia
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.09%
1.51%
자본화:
|
볼륨(24시간):